Clinical Trial Update: First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) [Phase 1, Phase 2]

View source ↗

Summary

Bayer's BAY2927088 is being investigated in a first-in-human Phase 1/2 study for adults with advanced non-small cell lung cancer harboring EGFR or HER2 mutation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BAY2927088

Snippet

Sponsor: Bayer | Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING